KRAS靶向治疗的临床进展：下一步何去何从？ - Suppr

Suppr

超能文献

Clinical progress of KRAS-targeted therapies: what next?

作者信息

Nagasaka Misako, Azmi Asfar S

机构信息

University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA.

Department of Internal Medicine, Division of Neurology, St. Marianna University, Kawasaki, Japan.

出版信息

Future Med Chem. 2022 Aug;14(15):1107-1110. doi: 10.4155/fmc-2022-0128. Epub 2022 Jun 27.

DOI:10.4155/fmc-2022-0128

PMID:35758004

Abstract

摘要

相似文献

Clinical progress of KRAS-targeted therapies: what next?

Future Med Chem. 2022 Aug;14(15):1107-1110. doi: 10.4155/fmc-2022-0128. Epub 2022 Jun 27.

Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.

Toxicol Appl Pharmacol. 2022 Apr 15;441:115988. doi: 10.1016/j.taap.2022.115988. Epub 2022 Mar 18.

SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.

Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3231-3238. doi: 10.1080/21691401.2019.1646748.

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.

Nat Med. 2018 Jul;24(7):954-960. doi: 10.1038/s41591-018-0024-8. Epub 2018 May 28.

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.

J Clin Invest. 2023 Apr 3;133(7):e164413. doi: 10.1172/JCI164413.

A saturation mutagenesis screen uncovers resistant and sensitizing secondary mutations to clinical KRAS inhibitors.

Proc Natl Acad Sci U S A. 2022 May 3;119(18):e2120512119. doi: 10.1073/pnas.2120512119. Epub 2022 Apr 26.

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28.

The Next Generation of KRAS Targeting: Reasons for Excitement and Concern.

Mol Cancer Ther. 2022 Nov 3;21(11):1645-1651. doi: 10.1158/1535-7163.MCT-22-0356.

PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.

Toxicol Appl Pharmacol. 2020 Jul 1;398:115019. doi: 10.1016/j.taap.2020.115019. Epub 2020 Apr 24.

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.

J Exp Med. 2021 Jan 4;218(1). doi: 10.1084/jem.20201414.

引用本文的文献

Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations.

NPJ Precis Oncol. 2025 Jun 13;9(1):182. doi: 10.1038/s41698-025-00993-8.

Detection and Quantitation of Endogenous Membrane-Bound RAS Proteins and KRAS Mutants in Cancer Cell Lines Using 1D-SDS-PAGE LC-MS.

Methods Mol Biol. 2024;2823:269-289. doi: 10.1007/978-1-0716-3922-1_17.

Quantitative Membrane Proteomics for Discovery of Actionable Drug Targets at the Surface of RAS-Driven Human Cancer Cells.

Methods Mol Biol. 2024;2823:27-46. doi: 10.1007/978-1-0716-3922-1_3.

The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy.

Cancer Manag Res. 2022 Dec 16;14:3485-3492. doi: 10.2147/CMAR.S387665. eCollection 2022.

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib.

Lung Cancer (Auckl). 2022 Nov 10;13:75-80. doi: 10.2147/LCTT.S383662. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Clinical progress of KRAS-targeted therapies: what next?

作者信息

Nagasaka Misako, Azmi Asfar S

机构信息

University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA.

Department of Internal Medicine, Division of Neurology, St. Marianna University, Kawasaki, Japan.

出版信息

Future Med Chem. 2022 Aug;14(15):1107-1110. doi: 10.4155/fmc-2022-0128. Epub 2022 Jun 27.

DOI:10.4155/fmc-2022-0128

PMID:35758004

Abstract

摘要

相似文献

Clinical progress of KRAS-targeted therapies: what next?

Future Med Chem. 2022 Aug;14(15):1107-1110. doi: 10.4155/fmc-2022-0128. Epub 2022 Jun 27.

Hexachlorophene, a selective SHP2 inhibitor, suppresses proliferation and metastasis of KRAS-mutant NSCLC cells by inhibiting RAS/MEK/ERK and PI3K/AKT signaling pathways.

Toxicol Appl Pharmacol. 2022 Apr 15;441:115988. doi: 10.1016/j.taap.2022.115988. Epub 2022 Mar 18.

SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.

Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):3231-3238. doi: 10.1080/21691401.2019.1646748.

Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase.

Nat Med. 2018 Jul;24(7):954-960. doi: 10.1038/s41591-018-0024-8. Epub 2018 May 28.

Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.

J Clin Invest. 2023 Apr 3;133(7):e164413. doi: 10.1172/JCI164413.

A saturation mutagenesis screen uncovers resistant and sensitizing secondary mutations to clinical KRAS inhibitors.

Proc Natl Acad Sci U S A. 2022 May 3;119(18):e2120512119. doi: 10.1073/pnas.2120512119. Epub 2022 Apr 26.

SHP2 is required for growth of KRAS-mutant non-small-cell lung cancer in vivo.

Nat Med. 2018 Jul;24(7):961-967. doi: 10.1038/s41591-018-0023-9. Epub 2018 May 28.

The Next Generation of KRAS Targeting: Reasons for Excitement and Concern.

Mol Cancer Ther. 2022 Nov 3;21(11):1645-1651. doi: 10.1158/1535-7163.MCT-22-0356.

PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.

Toxicol Appl Pharmacol. 2020 Jul 1;398:115019. doi: 10.1016/j.taap.2020.115019. Epub 2020 Apr 24.

SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling.

J Exp Med. 2021 Jan 4;218(1). doi: 10.1084/jem.20201414.

引用本文的文献

Augmenting precision medicine via targeted RNA-Seq detection of expressed mutations.

NPJ Precis Oncol. 2025 Jun 13;9(1):182. doi: 10.1038/s41698-025-00993-8.

Detection and Quantitation of Endogenous Membrane-Bound RAS Proteins and KRAS Mutants in Cancer Cell Lines Using 1D-SDS-PAGE LC-MS.

Methods Mol Biol. 2024;2823:269-289. doi: 10.1007/978-1-0716-3922-1_17.

Quantitative Membrane Proteomics for Discovery of Actionable Drug Targets at the Surface of RAS-Driven Human Cancer Cells.

Methods Mol Biol. 2024;2823:27-46. doi: 10.1007/978-1-0716-3922-1_3.

The Path to Personalized Treatment in KRAS-Mutant Non-Small Cell Lung Cancer: A Review of Targeted Therapies and Immunotherapy.

Cancer Manag Res. 2022 Dec 16;14:3485-3492. doi: 10.2147/CMAR.S387665. eCollection 2022.

A Long Overdue Targeted Treatment for KRAS Mutations in NSCLC: Spotlight on Adagrasib.

Lung Cancer (Auckl). 2022 Nov 10;13:75-80. doi: 10.2147/LCTT.S383662. eCollection 2022.